Software Platforms
Our Phoenix™ platform is the leading PK/PD modeling and simulation software used worldwide for non-compartmental analysis, population PK, and IVIVC.
Trusted by more than 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including the FDA, EMA, and PMDA, Phoenix features a user-friendly interface and built-in visualization and reporting tools to get the outputs you need.
Our last release includes open source plotting, upgrades to Reporter and Phoenix NLME, and more.
QSP has enormous potential to improve pharma R&D productivity. Most major pharma organizations are investing in it. QSP may also be able to leverage the enormous amounts of information we now have access to, including genomics and proteomics data.
With Simcyp’s QSP solutions, optimize drug discovery and development with quantitative systems pharmacology to more accurately correlate the physiological differences between preclinical models and human patients.
We have already established two QSP Consortia, in partnership with leading biopharmaceutical companies, to develop Immunogenicity and Immuno-oncology Simulators. A third QSP Consortia on Neurodegenerative Diseases is in progress.
9 out of 10 drugs in development fail to make it to market. Late stage failures are especially costly as companies have already invested hundreds of millions of dollars in earlier phases. One reason for trial failures is suboptimal trial design.
Our Trial Simulator™ has been used for over a decade by leading companies to maximize their chances of trial success. Leveraging existing knowledge for a drug under study with simulation, you can find answers to critical questions.
Using Trial Simulator, you can anticipate risks and preview the range of expected results before millions in R&D dollars are spent and human subjects are exposed to experimental therapies.
Certara also offers trial simulation and design consulting services.
Our people, your experts
Karen Yeo, PhD
Since 2002, Karen has led projects relating to the extrapolation of in vitro data to predict in vivo pharmacokinetics in humans. This has included development and implementation of the models into the Simcyp Simulator.
Piet van der Graaf, PhD
With over 15 years of experience working in the pharmaceutical industry at Sanofi and Pfizer, Piet bringss considerable skill and experience to QSP projects and contributes to the strategic development of Certara. He is also Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology.
Kevin Trimm, MSc
Kevin brings over 14 years of experience in pharmaceutical drug development and research. He spearheads the product strategy for the Phoenix platform and leads implementation of technology solutions, collaborating closely with clients.
Karen Yeo, PhD
Since 2002, Karen has led projects relating to the extrapolation of in vitro data to predict in vivo pharmacokinetics in humans. This has included development and implementation of the models into the Simcyp Simulator.
Piet van der Graaf, PhD
With over 15 years of experience working in the pharmaceutical industry at Sanofi and Pfizer, Piet bringss considerable skill and experience to QSP projects and contributes to the strategic development of Certara. He is also Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology.
Kevin Trimm, MSc
Kevin brings over 14 years of experience in pharmaceutical drug development and research. He spearheads the product strategy for the Phoenix platform and leads implementation of technology solutions, collaborating closely with clients.